Antimicrobial Resistance Funding Shortfalls Threaten Asia-Pacific Healthcare Systems
Antimicrobial resistance threatens lives across the Asia-Pacific region, yet half of the national action plans designed to combat the crisis lack funding, according to findings.
Regional Death Toll and Projected Losses
Looking forward, the World Health Organization Western Pacific Region projects that antimicrobial resistance will cause more than five million deaths and cost up to $148 billion between 2020 and 2030.
Saia Ma’u Piukala, WHO regional director for the Western Pacific, addressed the financial gap in a public statement. Countries in Asia and the Pacific have shown determination, leadership, and political commitment for concrete actions, but that commitment needs to be matched with the domestic investment required to implement ambitious national action plans, Piukala stated.
Evolution of National Action Plans
Government strategies to address the threat have grown more sophisticated over time. Among 28 countries presenting regional data, 27 have endorsed at least one multisectoral action plan. Most of these nations—specifically 14 governments—are currently implementing their second generation of plans, while three countries operate under their third iteration.
Second-generation plans show distinct structural improvements compared to initial frameworks:
- Costing integration: 67% of second-generation plans include cost estimates, compared to just 33% of first-generation plans.
- Monitoring frameworks: 93% incorporate monitoring and evaluation frameworks, up from 33%.
- Measurable targets: 71% include specific, measurable targets, compared to only 8% previously.
Persistent Funding Gaps Across 28 Nations
Despite stronger administrative frameworks, financial backing remains uneven across the 28 evaluated countries. Nearly half, or 49%, of the 27 countries with active plans have not costed their strategies at all. Only 44% of plans are fully costed, and 7% are partially costed.
Reliance on international donors creates ongoing vulnerabilities. Only eight nations—comprising a mix of high-income economies and Pacific island countries—fund their antimicrobial resistance activities entirely through domestic budgets. Meanwhile, 15 countries receive less than 30% of their total program funding from domestic sources.
Regional Initiatives Led by Japan and WHO
Multilateral efforts to accelerate regional response began in earnest in 2016. Japan launched the Asia-Pacific One Health Initiative on AMR (ASPIRE) that year, partnering with the WHO Regional Office for the Western Pacific and the WHO Regional Office for South-East Asia to coordinate cross-border containment strategies.
Nilesh Buddha, officer-in-charge for the WHO South-East Asia Region, emphasized the urgency of continued cooperation. The countries of Asia and the Pacific have made clear that they recognise the urgency of action, Buddha noted, adding that collaborative regional approaches can change the trajectory of resistance and protect future generations.
Frequently Asked Questions About Asia-Pacific Antimicrobial Resistance Plans
What specific funding threshold do most Asia-Pacific countries fail to meet?
Among 27 countries with endorsed action plans, 49% have not costed their initiatives at all, and 56% rely on external partners for more than 70% of their funding.
Which regional body initiated the ASPIRE framework in 2016?
Japan launched the Asia-Pacific One Health Initiative on AMR in 2016 alongside the WHO Regional Office for the Western Pacific and the WHO Regional Office for South-East Asia.
How many deaths were directly attributed to antimicrobial resistance in the region during 2019?
An estimated more than 680,000 lives were directly lost to resistant infections in 2019 out of 2.6 million total deaths associated with the condition.